...BND-001 by mid-2008. The newco will seek to raise a series A round by mid-2007. NiKem... ...hired as Brane's CSO and CMO. Giuseppe Giardina was promoted from COO to CEO of NiKem... ..."were formerly perceived as a potential 'conflict of interest' issue by some of NiKem's clients." NiKem Research s.r.l....
...The companies will use NiKem's chemistry and preclinical technologies to design, synthesize and optimize compounds against... ...IP. Financial terms of the one-year deal were not disclosed. Neurotune AG , Zurich, Switzerland NiKem Research s.r.l....
...The companies extended their cancer research deal under which NiKem is using its medicinal chemistry technology... ...medicinal chemistry technology to optimize Hybrigenics' inhibitors of ubiquitin-specific proteases. Hybrigenics SA , Paris, France NiKem...
...BND-001 by mid-2008. The newco will seek to raise a series A round by mid-2007. NiKem... ...hired as Brane's CSO and CMO. Giuseppe Giardina was promoted from COO to CEO of NiKem... ..."were formerly perceived as a potential 'conflict of interest' issue by some of NiKem's clients." NiKem Research s.r.l....
...The companies will use NiKem's chemistry and preclinical technologies to design, synthesize and optimize compounds against... ...IP. Financial terms of the one-year deal were not disclosed. Neurotune AG , Zurich, Switzerland NiKem Research s.r.l....
...The companies extended their cancer research deal under which NiKem is using its medicinal chemistry technology... ...medicinal chemistry technology to optimize Hybrigenics' inhibitors of ubiquitin-specific proteases. Hybrigenics SA , Paris, France NiKem...